Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
05/2003
05/30/2003WO2003043985A1 Heterocyclic compounds and methods of use
05/30/2003WO2003043982A1 Derivatives of andrimide and moiramide b having antibacterial properties
05/30/2003WO2003043668A2 Conditioning solution for contact lenses
05/30/2003WO2003043660A2 Composition for stabilizing hyaluronic acid
05/30/2003WO2003043657A1 Topical delivery of codrugs
05/30/2003WO2003043650A1 Use of fk506 and analogues for treating allergic diseases
05/30/2003WO2003043639A2 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER
05/30/2003WO2003043633A1 Use of an ascomycin for the treatment of blepharitis
05/30/2003WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003WO2003043548A1 Visco dye
05/30/2003WO2003013487A3 Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field
05/30/2003WO2002100328A3 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
05/30/2003WO2002096363A3 Method for treating fibrotic diseases or other indications
05/30/2003CA2467559A1 Topical delivery of codrugs
05/30/2003CA2467549A1 Use of an ascomycin for the treatment of blepharitis
05/30/2003CA2467242A1 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003CA2466925A1 Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
05/30/2003CA2466733A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003CA2466491A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003CA2466072A1 Substituted indolizine-like compounds and methods of use
05/30/2003CA2464957A1 Polypeptides of moraxella (branhamella) catarrhalis
05/30/2003CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/29/2003US20030100772 Oxygen-containing heterocyclic compounds
05/29/2003US20030100616 Administering to a patient for the treatment and/or prophylaxis an effective amount of 3-amino-propoxy derivative as a potent, beta-1-sepcific beta blocker whith a short duration of action in the systemic circulation
05/29/2003US20030100614 Use of thiamphenicol and derivatives thereof for the preparation of pharmaceutical compositions useful in the treatment of chlamydia pneumoniae infections
05/29/2003US20030100594 Carbonic anhydrase inhibitor
05/29/2003US20030100567 Tyrosine kinase inhibitors
05/29/2003US20030100564 Administering 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione and/or metabolite thereof; treating neoplastic diseases, atherosclerosis, restenosis, rheumatoid arthritis, Crohn's disease, diabetic retinopathy, psoriasis, and endometriosis
05/29/2003US20030100563 Such as 7-((3R)-3-amino-4-(3,4-difluorophenyl)butanoyl)-2-(trifluoromethyl)-5,6,7,8 -tetrahydroimidazo(1,2-a)pyrazine dihydrochloride for treatment of insulin resistance disorders
05/29/2003US20030100548 Antiarthritic agents; atherosclerosis and chronic obstructive pulmonary disease treatments
05/29/2003US20030100545 Psychological disorder treatments that increase the activity of cholinergic receptors
05/29/2003US20030100510 Crystallized structure of type IV collagen NC1 domain hexamer
05/29/2003US20030100503 Neurogenic compositions and methods
05/29/2003US20030099978 Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (EAOH)
05/29/2003US20030099718 Nanocrystalline antimicrobial metals (noble metals)formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal sufficient to cause microbiocidal effect; anti-inflammatory activity
05/29/2003US20030099694 Method for the improvement of transport across adaptable semi-permeable barriers
05/29/2003US20030099628 Preventing proliferation of a tumor, using heparinase III; use sequencing heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis
05/29/2003US20030099596 Treatment of macular edema
05/28/2003EP1314723A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/28/2003EP1314719A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
05/28/2003EP1314426A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/28/2003EP1313726A1 Quinoline derivatives having vegf inhibiting activity
05/28/2003EP1313721A2 Non-imidazole aryloxyalkylamines as h3 receptor ligands
05/28/2003EP1313714A1 Valsartan salts
05/28/2003EP1313711A2 Indazole derivatives as jnk inhibitors
05/28/2003EP1313705A1 Gem-substituted alpha v beta 3 integrin antagonists
05/28/2003EP1313512A1 Vascular endothelial growth factor 2
05/28/2003EP1313504A2 Methods and compositions for inhibiting angiogenesis
05/28/2003EP1313483A2 Methods for inducing apolipoprotein e secretion
05/28/2003EP1313470A1 Novel alicyclic imidazoles as h 3 agents
05/28/2003EP1313461A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
05/28/2003EP1313415A2 Devices for intraocular drug delivery
05/28/2003EP1232173B1 Fusidic acid derivatives
05/28/2003EP1206462B1 Heterocyclic compounds inhibiting angiogenesis
05/28/2003EP1165115B1 Modulation of vascular permeability by mean of tie2 receptor activators
05/28/2003EP1163239B1 Modified amino-acid amides as cgrp antagonists
05/28/2003EP1039904B1 Synergistic antimicrobial compositions
05/28/2003EP1032415B1 Composition for the treatment of allergic conditions with cysteine and serine proteinase inhibitors
05/28/2003EP0826373B1 Use of lactoferrin for preventing postoperative astigmatism
05/28/2003EP0788509B1 Therapeutic peptide derivatives
05/28/2003EP0786995B1 Use of 5-(tetradecyloxy)-2-furan carboxylic acid for treating alzheimer's disease or psychosis
05/28/2003EP0625904B1 Bimodal molecular weight hyaluronate formulations and methods for using same
05/28/2003CN1420933A Method of inducing angiogenesis by micro-organs
05/28/2003CN1420887A 8-quinolinxanthine and 8-isoquinolinxanthine derivs. as PDE 5 inhibitors
05/28/2003CN1420881A Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha
05/28/2003CN1420872A Caspase inhibitors and use thereof
05/28/2003CN1420865A Ocular hypotensive lipids
05/28/2003CN1420790A Transporters and drug delivery system by using same
05/28/2003CN1420788A Improved treatment of neovascularization
05/28/2003CN1420775A Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
05/28/2003CN1420120A Medicinal preparation contg. 1-N-ethyl vistamycin or its salt, and process for preparing same
05/28/2003CN1420114A 2,3-disubstd. -4(3H)-quinazolones
05/27/2003US6569904 Via administration of toremifene for treatment or prevention of systemic/pulmonary hypertension, fibrosis, bronchial asthma, respiratory distress syndrome, myocardial infarction, thrombosis, congestive heart failure, and renal failure
05/27/2003US6569890 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569884 Conformationally rigid bicyclic and adamantane derivatives useful as α2-adrenergic blocking agents
05/27/2003US6569871 Substituted imidazole compounds
05/27/2003US6569855 Particularly zinc metalloprotease activity for treatment of variety of maladies involving inflammation and/or tissue integrity
05/27/2003US6569443 Topical treatment or prevention of ocular infections
05/27/2003US6569428 For regulating angiogenesis; nucleic acid encoding an endothelial cell mitogen and endothelial cell progenitors, where the EC progenitors are CD34+, Flk-1+, and tie-2+
05/27/2003CA2412624A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurogenerative diseases
05/27/2003CA2412466A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/27/2003CA2231558C .gamma.-rar antagonist ligand or .alpha.-rar agonist ligand as an apoptosis inhibitor
05/27/2003CA2209391C New heterocyclic biaryl compounds and their use in human or veterinary medicine and in cosmetics
05/22/2003WO2003042390A1 Mammalian protein phosphatases
05/22/2003WO2003042357A2 Enzymes
05/22/2003WO2003042216A1 Polycyclic guanine derivative phosphodiesterase v inhibitors
05/22/2003WO2003042214A2 A2b adenosine receptor antagonists
05/22/2003WO2003042211A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
05/22/2003WO2003042210A1 Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
05/22/2003WO2003042207A1 Thiazolyl substituted triazoles as alk5 inhibitors
05/22/2003WO2003042205A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042191A1 Benzamide and heteroarylamide as p2x7 receptor antagonists
05/22/2003WO2003042190A1 N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
05/22/2003WO2003042177A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042176A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation
05/22/2003WO2003042174A1 Cannabinoid receptor ligands
05/22/2003WO2003042173A1 Nk1 antagonists
05/22/2003WO2003041707A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003WO2003041697A1 Method for treating autoimmune diseases
05/22/2003WO2002102836A3 Moraxella (branhamella) catarrhalis antigens
1 ... 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 ... 531